<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582176</url>
  </required_header>
  <id_info>
    <org_study_id>PERK2_KAH</org_study_id>
    <secondary_id>CDMRP-OR160026</secondary_id>
    <nct_id>NCT03582176</nct_id>
  </id_info>
  <brief_title>PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2</brief_title>
  <acronym>PERK2</acronym>
  <official_title>PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) is a Phase III randomized,&#xD;
      controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg&#xD;
      or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow&#xD;
      extension-flexion range of motion (ROM) arc at 12 weeks post-randomization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK2) is a Phase III randomized,&#xD;
      controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg&#xD;
      or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow&#xD;
      extension-flexion range of motion (ROM) arc at 12 weeks post-randomization. The Research&#xD;
      Hypothesis is that Ketotifen is superior to a lactose placebo in reducing joint contracture&#xD;
      severity in adult participants with isolated elbow fractures or dislocations. The Primary&#xD;
      Objective is to determine if Ketotifen given within 7 days of injury can reduce&#xD;
      post-traumatic elbow joint contractures when compared to placebo. The Secondary Objectives&#xD;
      are: 1) to ascertain the optimal dose of Ketotifen and 2) to compare adverse events in&#xD;
      Ketotifen and placebo groups.&#xD;
&#xD;
      Inclusion criteria: age ≥ 18 years old and skeletally mature; distal humerus (AO/OTA type 13)&#xD;
      and/or proximal ulna and/or proximal radius fractures (AO/OTA type 2U1/2R1) and/or elbow&#xD;
      dislocations (open fractures with or without nerve injury may be included); injury ≤ 7 days;&#xD;
      ability to give informed consent; able to comply with protocol and follow up; operative&#xD;
      treatment of the elbow fracture or dislocation; participant has negative urine or blood serum&#xD;
      pregnancy test.&#xD;
&#xD;
      Exclusion criteria: Pre-existing elbow contracture; elbow arthritis (osteoarthritis,&#xD;
      inflammatory arthritis, or nonspecific monoarticular arthritis); inability to mobilize elbow&#xD;
      within 21 days of injury; bilateral elbow injury; oral hypoglycemic medications; history of&#xD;
      epilepsy; lactose intolerance; language or cognitive difficulties preventing completion of&#xD;
      questionnaires; pregnancy; breast feeding; male or female unwilling to use 2 methods of&#xD;
      contraception; total elbow replacement planned for treatment of fracture or dislocation;&#xD;
      prior elbow injury or operation; concomittant musculoskeletal or visceral injuries preventing&#xD;
      post-operative elbow therapy; severe renal and hepatic impairment.&#xD;
&#xD;
      Outcome Measures: Range of motion; Disability Arm, Shoulder, Hand; Oxford Elbow Score; Pain&#xD;
      Catastrophizing Scale; standardized case report form; radiographic evaluation for fracture&#xD;
      healing/non-union; and number of participants requiring reoperation for all elbow related&#xD;
      causes, and post-traumatic joint contractures, 2 - 52 weeks post-randomization.&#xD;
&#xD;
      Safety Endpoints: The main safety endpoint for this study is the frequency of adverse events&#xD;
      and serious adverse events, and radiographic assessment for non-union and heterotopic&#xD;
      ossification (HO), 2 - 52 weeks post-randomization.&#xD;
&#xD;
      Ketotifen is the first and only agent demonstrating a significant decrease in contracture&#xD;
      severity in preclinical trials that also has a wide safety profile. Ketotifen has been used&#xD;
      in the treatment of chronic asthma for over 40 years in humans. Ketotifen is a medication&#xD;
      that has anti-anaphylactic properties, due to the prevention of the synthesis and/or release&#xD;
      of growth factors and mediators, as well as antihistamine affects due to H1 receptor&#xD;
      antagonism. Post market surveillance has confirmed the safety of Ketotifen. A Phase II RCT&#xD;
      comparing a single dose of Ketotifen (5 mg) to placebo in elbow fractures or dislocations in&#xD;
      Calgary (ClinicalTrials.gov Identifier NCT01902017), demonstrated safety of Ketotifen and&#xD;
      coupled with preclinical animal studies informed the need to increase the sample size,&#xD;
      examine multiple doses, and narrow the study population to more severe injuries requiring an&#xD;
      operation in the Phase III RCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">September 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elbow Extension-Flexion Arc of Motion</measure>
    <time_frame>12 weeks post-randomization</time_frame>
    <description>The change in range of motion between baseline and 12 weeks post-randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of Motion at other time points</measure>
    <time_frame>6 weeks, 24 weeks, 52 weeks</time_frame>
    <description>Elbow extension-flexion arc of motion, forearm pronation-supination arc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures</measure>
    <time_frame>Enrolment - 52 weeks</time_frame>
    <description>Disability of the Arm, Shoulder and Hand (DASH) The upper extremity scoring scale DASH is a validated tool for disorders of the elbow with a range from 0 (least disability) to 100 (most disability). Ten is the average score in the general population and the minimal clinically important difference (MCID) is 10. DASH contains 30 questions asking participants about their ability to perform activities and their symptoms. Each question ranges from 1 (no difficulty) to 5 (unable). There is also optional work and sports/performing arts modules.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures</measure>
    <time_frame>Enrolment - 52 weeks</time_frame>
    <description>Oxford Elbow Score (OES). The OES is a 12-item questionnaire that is a valid measure of the outcome of surgery of the elbow in English (UK). It's 3 unidimensional domains include elbow function, pain, and social-psychological and the values range from 0 (greatest severity) to 100 (least severity). The OES has been used in trauma populations and its MCID is 10 for the elbow function domain and 18 for the pain and social-psychological domains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures</measure>
    <time_frame>Enrolment - 52 weeks</time_frame>
    <description>Pain Catastrophizing Scale (PCS). The PCS is a 13-item instrument that can be completed in 5 minutes and requires a Grade 6 level of reading. For each question the participant has a choice from a range of 0 (not at all) to 4 (all the time). There are 3 subscale scores assessing rumination, magnification, and helplessness that are combined into an overall score. PCS total scores range from 0 - 52. Research at the University Centre for Research on Pain and Disability indicates that a total PCS score of 30 represents clinically relevant level of catastrophizing. It has been used in the assessment of injuries to the elbow, wrist, and hand where results are dependent on this behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographs</measure>
    <time_frame>Enrolment - 52 weeks</time_frame>
    <description>Radiographic evaluation for fracture healing and/or nonunion, and the number of participants requiring re-operation for contracture and also composite re-operation for all elbow related causes. This will be completed by a radiologist.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">702</enrollment>
  <condition>Elbow Fracture</condition>
  <condition>Elbow Injury</condition>
  <condition>Elbow Dislocation</condition>
  <arm_group>
    <arm_group_label>Lactose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose Placebo by mouth twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketotifen Fumarate - 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketotifen Fumarate 2 mg by mouth twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketotifen Fumarate - 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketotifen Fumarate 5 mg by mouth twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose Placebo</intervention_name>
    <description>One capsule by mouth twice per day</description>
    <arm_group_label>Lactose Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketotifen Fumarate 2mg</intervention_name>
    <description>2 mg tablets (over-encapsulated into one capsule) by mouth twice per day</description>
    <arm_group_label>Ketotifen Fumarate - 2mg</arm_group_label>
    <arm_group_label>Ketotifen Fumarate - 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketotifen Fumarate 5mg</intervention_name>
    <description>5 mg tablets (over-encapsulated into one capsule) by mouth twice per day</description>
    <arm_group_label>Ketotifen Fumarate - 2mg</arm_group_label>
    <arm_group_label>Ketotifen Fumarate - 5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old; skeletally mature with no growth plates in the elbow&#xD;
&#xD;
          -  Distal humerus (AO/OTA type 13) and/or proximal ulna and/or proximal radius fractures&#xD;
             (AO/OTA type 2U1 or 2R1) and/or elbow dislocations (open fractures with or without&#xD;
             nerve injury may be included)&#xD;
&#xD;
          -  Operative treatment of the elbow fracture or dislocation&#xD;
&#xD;
          -  Injury ≤ 7 days&#xD;
&#xD;
          -  Participant has a negative urine or blood serum pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing elbow contracture&#xD;
&#xD;
          -  Elbow arthritis (osteoarthritis, inflammatory arthritis, or nonspecific monoarticular&#xD;
             arthritis)&#xD;
&#xD;
          -  Inability to mobilize elbow within 21 days of injury&#xD;
&#xD;
          -  Bilateral elbow injury&#xD;
&#xD;
          -  Concomitant musculoskeletal or visceral injuries preventing post-operative elbow&#xD;
             therapy&#xD;
&#xD;
          -  Oral hypoglycemic medications&#xD;
&#xD;
          -  History of epilepsy&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Language or Cognitive difficulties preventing reliable completion of questionnaires&#xD;
&#xD;
          -  Females who are pregnant or breast feeding&#xD;
&#xD;
          -  Females of reproductive age or males unwilling to use 2 effective methods of&#xD;
             contraception&#xD;
&#xD;
          -  Severe renal impairment&#xD;
&#xD;
          -  Severe hepatic impairment&#xD;
&#xD;
          -  Prior elbow injury or operation&#xD;
&#xD;
          -  Total elbow replacement planned for treatment of injury&#xD;
&#xD;
          -  Unlikely to maintain follow up (no fixed address, plans to move out of town in the&#xD;
             next year, states unable to comply with protocol)&#xD;
&#xD;
          -  Unwilling or unable to provide written informed consent for trial participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin A Hildebrand, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary and Alberta Health Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerardo Duque, MA</last_name>
    <phone>403-943-5556</phone>
    <email>Gerardo.duque@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin A Hildebrand, MD, FRCSC</last_name>
    <phone>403-220-7282</phone>
    <email>hildebrk@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland Medical Centre</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Rudnicki, BEXSc</last_name>
      <phone>410-706-1604</phone>
      <email>JRudnicki@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Raymond Pensy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Churchill, MA</last_name>
      <phone>704-355-6947</phone>
      <email>Christine.Churchill@atriumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Seymore, PhD</last_name>
      <phone>704-355-6969</phone>
      <email>Rachel.Seymour@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence Kempton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Cuke, Msc</last_name>
      <phone>802-656-8396</phone>
      <email>Melissa.Cuke@uvmhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michel Benoit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter Lougheed Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Duque, MA</last_name>
      <phone>403-943-5556</phone>
      <email>gerardo.duque@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Taylor Stranaghan, BHK</last_name>
      <phone>403-943-5537</phone>
      <email>taylor.stranaghan@ucalgary.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Hildebrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aaron Bois, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raul Kuchinad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy LaMothe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Le, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Longino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Rezansoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iain Russell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajrishi Sharma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelcie Witges</last_name>
      <phone>403-944-4594</phone>
      <email>kmwitges@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Prism Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rockyview General Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Johnston, MD</last_name>
      <email>kelly.johnston0@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kelly Johnston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Health Campus</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenna Mattiello</last_name>
      <phone>403-956-3687</phone>
      <email>brenna.mattiello1@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Neil White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Dodd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sturgeon Community Hospital</name>
      <address>
        <city>St. Albert</city>
        <state>Alberta</state>
        <zip>T8N 6C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liane Jean</last_name>
      <email>Liane.Jean@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Robert Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbia Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyrsten Payne</last_name>
      <phone>604-520-4963</phone>
      <email>kyrsten.payne@fraserhealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ella Spicer</last_name>
      <email>ella.spicer@fraserhealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Farhad Moola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zafeiria Glaris</last_name>
      <email>zafeiria.glaris@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Thomas Goetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Trask, MSc</last_name>
      <phone>902-473-3161</phone>
      <email>Kelly.Trask@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Trenholm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Care London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Munro, CCRA HIM</last_name>
      <email>Katrina.Munro@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Graham King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie McIlquham, BScHK</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>79839</phone_ext>
      <email>kmcilquham@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>J Pollock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Civic Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Dodd-Moher</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>19217</phone_ext>
      <email>medodd@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Steve Papp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrine Milner</last_name>
      <phone>416-505-7686</phone>
      <email>Katrine.Milner@Sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Monica Kunz</last_name>
      <email>Monica.Kunz@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Diane Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Vicente, RN</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>2608</phone_ext>
      <email>VicenteM@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Aaron Nauth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Amedeo</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>43386</phone_ext>
      <email>Mary.Amedeo@MUHC.MCGILL.CA</email>
    </contact>
    <investigator>
      <last_name>Ed Harvey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Kevin Hildebrand</investigator_full_name>
    <investigator_title>Professor Department of Surgery, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute elbow fractures and/or dislocations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Dislocations</mesh_term>
    <mesh_term>Contracture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketotifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

